An Open-Label, Randomized, Multicenter Phase IIa Study Evaluating Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Minimum (trough) pertuzumab concentration (Cmin)
Day 43
No
Clinical Trials
Study Director
Hoffmann-La Roche
Italy: Ministry of Health
BP27836
NCT01461057
December 2011
May 2016
Name | Location |
---|